Calvo Elected for Second Term at EMA
Dr. Gonzalo Calvo has been re-elected by the Healthcare Professionals’ Working Party (HCPWP) of the European Medicines Agency (EMA) as its co-chair.
The Healthcare Professionals' Working Party (HCPWP) of the European Medicines Agency (EMA) has re-elected Dr. Gonzalo Calvo as its co-chair.
Calvo, a physician and consultant in clinical pharmacology from Barcelona, Spain, has extensive experience in medicines regulation, including nearly 10 years as a member of EMA’s Committee for Medicinal Products for Human Use (CHMP).
“My aim is to consolidate the work initiated and open new paths to strengthen the role and impact of healthcare professionals in regulatory activities, securing fast and safe access to new medicines,” said Calvo. “Close collaboration with the patients and consumers’ working group has been instrumental for the progress of HCPWP work. I do not see any other way forward than enhancing our interaction with patients and consumers.”
Together with Isabelle Moulon, Head of the Public Engagement Department at EMA, he will co-chair HCPWP for the next three years.
No decision was reached, however, on the new co-chair of the Patients' and Consumers' Working Party (PCWP).
The main role of the PCWP and the HCPWP is to provide recommendations to EMA and its scientific committees on all matters of interest to either patients and consumers or healthcare professionals in relation to medicines, as well as to monitor interactions between the agency and patients, consumers and healthcare professionals.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
